Cited by 179Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy

Open access

Lee, Dae Ho, Park, Keunchil, Kim, Joo Hang, Lee, Jong-Seok, Shin, Sang Won, Kang, Jin-Hyoung, Ahn, Myung-Ju, Ahn, Jin Seok, Suh, Cheolwon, Kim, Sang-We·2010·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-09-1903

Open this paper in CoChat — free account Open PDF

Abstract

Purpose: The ISTANA (IRESSA as Second-line Therapy in Advanced NSCLC—KoreA) study compared gefitinib with docetaxel in patients with advanced or metastatic non–small cell lung carcinoma (NSCLC) pretreated with platinum-based chemotherapy. Experimental Design: We conducted a multicenter, randomized, open-label phase III trial of gefitinib (250 mg/d) versus docetaxel (75 mg/m2 day 1 every 3 weeks) in patients with advanced or metastatic NSCLC treated with one previous platinum-based chemotherapy. The primary endpoint was progression-free survival. Results: A total of 161 patients (male, 62%; never smoker, 41%; adenocarcinoma, 68%) were enrolled. Progression-free survival was longer for gefitinib compared with docetaxel (hazard ratio, 0.729; 90% confidence interval, 0.533-0.998; one-sided P = 0.0441). Gefitinib significantly improved objective response rate (28.1% versus 7.6%; two-sided P = 0.0007). In the final analysis of overall survival, the hazard ratio was 0.870 (95% confidence interval, 0.613-1.236; two-sided P = 0.4370). No significant differences were seen in the quality of life or symptom improvement rates between the two treatment groups. Gefitinib was well tolerated, was consistent with previous data and disease, and had fewer serious adverse events and fewer Common Terminology Criteria for Adverse Events grade 3 or 4 adverse events than docetaxel. The incidence of interstitial lung disease–type events was 3.7% (n = 3) with gefitinib and 3.9% (n = 3) with docetaxel. Conclusions: The primary endpoint of progression-free survival was longer with gefitinib than docetaxel, and the secondary endpoints showed superior objective response rate, good tolerability, and similar quality of life improvement rates for gefitinib than docetaxel. Therefore, gefitinib is an important valid treatment option for second-line therapy for Korean NSCLC patients. Clin Cancer Res; 16(4); 1307–14

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-09-1903

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citation
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
Shepherd, F. A., Dancey, J. E., Ramlau, R., Mattson, K. V., Gralla, R. J., O’Rourke, M. A., Levitan, N. I., Gressot, L., Vincent, M. D., Burkes, R. L., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,178
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079
Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
Fossella, F. V., DeVore, R. F., Kerr, R. N., Crawford, J., Natale, R. R., Dunphy, F., Kalman, L. A., Miller, V. A., Lee, J. S., Moore, M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2354 · Cited by 1,360
Self-citation
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Kim, E. S., Hirsh, V., Mok, T. S. K., Socinski, M. A., Gervais, R., Wu, Y.-L. L. C., Li, L.-Y., Watkins, C. L., Sellers, M. V., Lowe, E., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61758-4 · Cited by 1,241
Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib
Han, S., Kim, T., Hwang, P. G., Jeong, S., Kim, J., Choi, I. S., Oh, D., Kim, J. H., Kim, D., Chung, D. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.388 · Cited by 757
Self-citation

Show all 16 references

Sorted by citations

Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Masters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Brahmer, J. R., Ellis, P. M., Gajra, A., Rackear, N., Schiller, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1342 · Cited by 850
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
(2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.05.01 · Cited by 716
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
Garassino, M. C., Martelli, O., Broggini, M., Farina, G., Veronese, S., Rulli, E., Bianchi, F., Bettini, A., Longo, F., Moscetti, L., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70310-3 · Cited by 475
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
Shi, Y., Zhang, L., Liu, X., Zhou, C., Zhang, L., Zhang, S., Wang, D., Li, Q., Qin, S., Hu, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70355-3 · Cited by 425
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
Wu, Y.-L., Lu, S., Cheng, Y., Zhou, C., Wang, J., Mok, T., Zhang, L., Tu, H.-Y., Wu, L., Feng, J., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.01.006 · Cited by 357
Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)
Kawaguchi, T., Ando, M., Asami, K., Okano, Y., Fukuda, M., Nakagawa, H., Ibata, H., Kozuki, T., Endo, T., Tamura, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.4694 · Cited by 260
NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology
Febbo, P. G., Ladanyi, M., Aldape, K., Marzo, A. M. D., Hammond, M. E. H., Hayes, D. F., Iafrate, A. J., Kelley, R. K., Marcucci, G., Ogino, S., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0137 · Cited by 262
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease
Besse, B., Adjei, A., Baas, P., Meldgaard, P., Nicolson, M. C., Paz-Ares, L. G., Reck, M., Smit, E. F., Syrigos, K., Stahel, R. A., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu123 · Cited by 250
EGFR-mutated lung cancer: a paradigm of molecular oncology
Zhang, Z., Stiegler, A. L., Boggon, T. J., Kobayashi, S., & Halmos, B. (2010) · Oncotarget · doi:10.18632/oncotarget.186 · Cited by 197
Targeted therapies for treatment of non‐small cell lung cancer—Recent advances and future perspectives
Minguet, J., Smith, K. H., & Bramlage, P. (2015) · International Journal of Cancer · doi:10.1002/ijc.29915 · Cited by 198
Treatment of Stage IV Non-small Cell Lung Cancer
Socinski, M. A., Evans, T. L., Gettinger, S. N., Hensing, T. A., Sequist, L. V. D., Ireland, B. K., & Stinchcombe, T. E. (2013) · CHEST Journal · doi:10.1378/chest.12-2361 · Cited by 206
Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose
Kenmotsu, H., & Tanigawara, Y. (2015) · Cancer Science · doi:10.1111/cas.12647 · Cited by 177
Network meta-analysis of survival data with fractional polynomials
Jansen, J. P. (2011) · BMC Medical Research Methodology · doi:10.1186/1471-2288-11-61 · Cited by 168
Treatment of advanced non small cell lung cancer.
Bareschino, M. A., Schettino, C., Rossi, A., Maione, P., Sacco, P. C., Zeppa, R., & Gridelli, C. (2011) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2010.12.08 · Cited by 161
Gefitinib and Erlotinib in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis of Toxicity and Efficacy of Randomized Clinical Trials
Burotto, M., Manasanch, E. E., Wilkerson, J., & Fojo, T. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0154 · Cited by 158
EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects
Soria, J., Mok, T. S. K., Cappuzzo, F., & Janne, P. A. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.10.003 · Cited by 131
Targeted therapy for non-small-cell lung cancer: past, present and future
Forde, P. M., & Ettinger, D. S. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.47 · Cited by 123
Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study
Karampeazis, A., Voutsina, A., Souglakos, J., Kentepozidis, N., Giassas, S., Christofillakis, C., Kotsakis, A., Papakotoulas, P., Rapti, A., Agelidou, M., et al. (2013) · Cancer · doi:10.1002/cncr.28132 · Cited by 113
Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials
Shi, L., Tang, J., Li, T., & Liu, Z. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.016 · Cited by 115
Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)
Kobayashi, K., & Hagiwara, K. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0258-9 · Cited by 110
Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 Trial
Oizumi, S., Kobayashi, K., Inoue, A., Maemondo, M., Sugawara, S., Yoshizawa, H., Isobe, H., Harada, M., Kinoshita, I., Okinaga, S., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0426 · Cited by 101
Pruritus in patients treated with targeted cancer therapies: Systematic review and meta-analysis
Ensslin, C. J., Rosen, A. C., Wu, S., & Lacouture, M. E. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.06.038 · Cited by 102
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy
Kim, S. T., Uhm, J. E., Lee, J., Sun, J., Sohn, I., Kim, S. W., Jung, S., Park, Y. H., Ahn, J. S., Park, K., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.05.022 · Cited by 99
Self-citation
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary
Hanna, N. H., Johnson, D. H., Temin, S., & Masters, G. A. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.026716 · Cited by 105
Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients
Suh, C. H., Park, H. S., Kim, K. W., Pyo, J., Hatabu, H., & Nishino, M. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.06.032 · Cited by 97
Self-citation
Gefitinib versus pemetrexed as second‐line treatment in patients with nonsmall cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01)
Sun, J., Lee, K. H., Kim, S.-W., Lee, K. H., Min, Y. J., Yun, H., Kim, H. K., SONG, H. S., Kim, Y. H., Kim, B., et al. (2012) · Cancer · doi:10.1002/cncr.27630 · Cited by 96
Self-citation
Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy
Domvri, K., Zarogoulidis, P., Darwiche, K., Browning, R. F., Jr., Li, Q., Turner, J. F., Kioumis, I. P., Spyratos, D., Porpodis, Κ., Papaiwannou, A., et al. (2013) · Journal of Cancer · doi:10.7150/jca.7734 · Cited by 82
Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint
Rulli, E., Ghilotti, F., Biagioli, E. C., Porcu, L., Marabese, M., D’Incalci, M., Bellocco, R., & Torri, V. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0302-8 · Cited by 86
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects
Bronte, G., Rolfo, C. D., Giovannetti, E., Cicero, G., Pauwels, P., Passiglia, F., Castiglia, M., Rizzo, S., Vullo, F. L., Fiorentino, E., et al. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.08.003 · Cited by 78
Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials
Qi, W., Sun, Y., Shen, Z., & Yao, Y. (2014) · Journal of Chemotherapy · doi:10.1179/1973947814y.0000000189 · Cited by 76
Targeting EGFR in non-small-cell lung cancer: Lessons, experiences, strategies
Stella, G. M., Luisetti, M., Inghilleri, S., Cemmi, F., Scabini, R., Zorzetto, M., & Pozzi, E. (2011) · Respiratory Medicine · doi:10.1016/j.rmed.2011.10.015 · Cited by 73
Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib, Erlotinib, Afatinib, Dacomitinib, and Icotinib in the Treatment of Non-Small-Cell Lung Cancer: A Systematic Review
Ellis, P. M., Coakley, N., Feld, R. D., Kuruvilla, S., & Ung, Y. (2015) · Current Oncology · doi:10.3747/co.22.2566 · Cited by 71
Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review
Baas, J. M., Krens, L. L., Guchelaar, H., Ouwerkerk, J., de Jong, F. A., Lavrijsen, A. P. M., & Gelderblom, H. A. J. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.09.004 · Cited by 68
Gefitinib for advanced non-small cell lung cancer
Sim, E., Yang, I. A., Wood-Baker, R. R., Bowman, R., & Fong, K. M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006847.pub2 · Cited by 71
Gefitinib: a review of its use in adults with advanced non-small cell lung cancer
Dhillon, S. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0358-9 · Cited by 68
Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial
Zhou, Q. H., Cheng, Y., Yang, J., Zhao, M., Zhang, L., Zhang, X.-C., Chen, Z., Yan, H., Song, Y., Chen, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu463 · Cited by 66
Prognostic and Predictive Value of K-RAS Mutations in Non-Small Cell Lung Cancer
Califano, R., Landi, L. M., & Cappuzzo, F. (2012) · Drugs · doi:10.2165/1163012-s0-000000000-00000 · Cited by 65
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: A systematic review
Murphy, M. P., & Stordal, B. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.02.004 · Cited by 63
Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis
Zhao, Y., Cheng, B., Chen, Z., Li, J., Liang, H., Chen, Y., Zhu, F., Li, C., Xu, K., Xiong, S., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103305 · Cited by 65
A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer
Vancheri, C., & du Bois, R. M. (2012) · European Respiratory Journal · doi:10.1183/09031936.00115112 · Cited by 62
Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications
Marchetti, A., Grammastro, M. D., Filice, G., Felicioni, L., Rossi, G., Graziano, P., Sartori, G., Leone, A., Malatesta, S., Iacono, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042164 · Cited by 59
Targeted therapy-induced diarrhea: A review of the literature
Pessi, M. A., Zilembo, N., Haspinger, E. R., Molino, L., Cosimo, S. D., Garassino, M. C., & Ripamonti, C. I. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.11.008 · Cited by 58
Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study
Migliorino, M. R., Santo, A., Romano, G., Cortinovis, D. L., Galetta, D., Alabiso, O., Cartenì, G., Vari, S., Fasola, G., Pazzola, A., et al. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2326-x · Cited by 58
Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
Araki, T., Yashima, H., Shimizu, K., Aomori, T., Hashita, T., Kaira, K., Nakamura, T., & Yamamoto, K. (2012) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7340 · Cited by 59
Folliculitis Induced by EGFR Inhibitors, Preventive and Curative Efficacy of Tetracyclines in the Management and Incidence Rates According to the Type of EGFR Inhibitor Administered: A Systematic Literature Review
Bachet, J., Peuvrel, L., Bachmeyer, C., Reguiaï, Z., Gourraud, P., Bouché, O., Ychou, M., Bensadoun, R., Dréno, B., & André, T. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0365 · Cited by 53
Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis
Elting, L. S., Chang, Y.-C., Parelkar, P., Boers-Doets, C. B., Michelet, M., Hita, A. G., Rouleau, T., Cooksley, C. D., Halm, J. K., Vithala, M. V., et al. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-013-1821-8 · Cited by 55
Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
Tiseo, M. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s6594 · Cited by 51
Incidence and risk of xerosis with targeted anticancer therapies
Valentine, J., Belum, V. R., Duran, J., Ciccolini, K. T., Schindler, K., Wu, S., & Lacouture, M. E. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.12.010 · Cited by 53
Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review
Karlsen, E., Kahler, S. L., Tefay, J., Joseph, S. R., & Simpson, F. (2021) · Cells · doi:10.3390/cells10051206 · Cited by 52
Phase III, randomized, open‐label, first‐line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non‐small‐cell lung cancer: evaluation of patients recruited from mainland China
Wu, Y.-L. L. C., Chu, D.-T., Han, B., Liu, X., Zhang, L., Zhou, C., Liao, M., Mok, T. S. K., Jiang, H., Duffield, E. L., et al. (2012) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2012.01518.x · Cited by 47
Comparison of the Efficacy and Safety of EFGR Tyrosine Kinase Inhibitor Monotherapy with Standard Second-line Chemotherapy in Previously Treated Advanced Non-small-cell Lung Cancer: a Systematic Review and Meta-analysis
Qi, W., Shen, Z., Lin, F., Sun, Y., Min, D., Tang, L., He, A., & Yao, Y. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.10.5177 · Cited by 46
The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer
Armour, A. A., & Watkins, C. L. (2010) · European Respiratory Review · doi:10.1183/09059180.00005110 · Cited by 47
Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC
Pallis, A. G., & Syrigos, K. N. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2012.12.025 · Cited by 44
Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
(2010) · Europe PMC (PubMed Central) · Cited by 41
Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation
Greenhalgh, J., Bagust, A., Boland, A., Dwan, K. M., Beale, S., Hounsome, J. C., Proudlove, C., Dundar, Y., Richardson, M., Dickson, R., et al. (2015) · Health Technology Assessment · doi:10.3310/hta19470 · Cited by 41
A randomized phase 2 trial of erlotinib versus pemetrexed as second‐line therapy in the treatment of patients with advanced EGFR wild‐type and EGFR FISH‐positive lung adenocarcinoma
Li, N., Ou, W., Yang, H., Liu, Q., Zhang, S., Wang, B.-X., & Wang, S. (2014) · Cancer · doi:10.1002/cncr.28591 · Cited by 40
Postprogression Survival in Patients With Advanced Non–Small-Cell Lung Cancer Who Receive Second-Line or Third-Line Chemotherapy
Hayashi, H., Okamoto, I., Taguri, M., Morita, S., & Nakagawa, K. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.09.006 · Cited by 40
First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients
Salazar, F., Molina‐Vila, M. Á., Sanchez-Ronco, M., Morán, T., Ramírez, J. L., Sánchez, J. M., Stahel, R. A., Garrido, P., Cobo, M., Isla, D., et al. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.07.008 · Cited by 40
Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection
Jeon, J. H., Kang, C. H., Kim, H.-S., Seong, Y. W., Park, I. K., & Kim, Y. T. (2014) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezu177 · Cited by 40
Establishing an EGFR mutation screening service for non-small cell lung cancer – Sample quality criteria and candidate histological predictors
Leary, A. F., de Castro, D. G., Nicholson, A. G., Ashley, S. E., Wotherspoon, A. C., O'Brien, M. E. R., & Popat, S. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.09.022 · Cited by 40
Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer
Zámečnı́kova, A. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.865012 · Cited by 40
Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors
Peng, Y., Li, Q., Zhang, J., Shen, W., Zhang, X., Sun, C., & Cui, H. (2018) · BioScience Trends · doi:10.5582/bst.2018.01246 · Cited by 38
Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy
Kim, S. T., Lee, J., Kim, J., Won, Y., Sun, J., Yun, J., Park, Y. H., Ahn, J. S., Park, K., & Ahn, M. (2010) · Cancer · doi:10.1002/cncr.25130 · Cited by 37
Self-citation
Gefitinib in Non Small Cell Lung Cancer
Costanzo, R., Piccirillo, M. C., Sandomenico, C., Carillio, G., Montanino, A., Daniele, G., Giordano, P., Bryce, J., Feo, G. D., Maïo, M. D., et al. (2011) · BioMed Research International · doi:10.1155/2011/815269 · Cited by 37
Meta-Analysis of EGFR Tyrosine Kinase Inhibitors Compared with Chemotherapy as Second-Line Treatment in Pretreated Advanced Non-Small Cell Lung Cancer
Li, N., Yang, L., Ou, W., Zhang, L., Zhang, S.-L., & Wang, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102777 · Cited by 35
Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials
Bailey, C. H., Jameson, G., Chao Sima, A., Fleck, S., White, E., Hoff, D. D. V., & Weiss, G. J. (2012) · Journal of Cancer · doi:10.7150/jca.3.7 · Cited by 35
Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?
Rossi, A., Pasquale, R., Esposito, C., & Normanno, N. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.09.001 · Cited by 31
Pulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer
Hong, D., Zhang, G., Zhang, X., & Liang, X. (2016) · Medicine · doi:10.1097/md.0000000000003008 · Cited by 30
Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy
Felip, E., Hirsh, V., Popat, S., Cobo, M., Fülöp, A., Dayen, C., Trigo, J. M., Gregg, R. W., Waller, C. F., Soria, J., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.06.002 · Cited by 30
Prospective Study of Gefitinib Readministration After Chemotherapy in Patients With Advanced Non–Small-Cell Lung Cancer Who Previously Responded to Gefitinib
Koizumi, T., Agatsuma, T., Ikegami, K., Suzuki, T., Kobayashi, T., Kanda, S., Yoshikawa, S., Kubo, K., Shiina, T., Takasuna, K., et al. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.01.006 · Cited by 30
An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer
Horgan, A. M., Bradbury, P. A., Amir, E., Ng, R., Douillard, J., Kim, E. S., Shepherd, F. A., & Leighl, N. B. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq682 · Cited by 29
The need for third-line treatment in non-small cell lung cancer: an overview of new options.
Syrigos, K., Saif, M. W., Karapanagiotou, E. M., Oikonomopoulos, G., & de Marinis, F. (2011) · PubMed · Cited by 28
Transglutaminase 2 Expression Predicts Progression Free Survival in Non-Small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Jeong, J.-H., Cho, B. C., Shim, H. S., Kim, H. R., Lim, S.-M., Kim, S. I., Chung, K. Y., Islam, S. M. B. U., Song, J. J., Kim, S., et al. (2013) · Journal of Korean Medical Science · doi:10.3346/jkms.2013.28.7.1005 · Cited by 28
Self-citation
Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials
Santoni, M., Conti, A., Andrikou, K., Bittoni, A., Lanese, A., Pistelli, M., Pantano, F., Vincenzi, B., Armento, G., Massari, F., et al. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.05.007 · Cited by 27
Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung
Goss, G. D., & Spaans, J. N. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0209 · Cited by 28
Tyrosine Kinase Inhibitors and their role in treating neovascular age-related macular degeneration and diabetic macular oedema
Chandra, S., Tan, E. Y., Empeslidis, T., & Sivaprasad, S. (2023) · Eye · doi:10.1038/s41433-023-02610-z · Cited by 27
Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis
Cromwell, I., van der Hoek, K., Melosky, B. L., & Peacock, S. J. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31822f657a · Cited by 27
Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors ? -- A literature-based meta-analysis
Xu, C., Zhou, Q. H., & Wu, Y.-L. L. C. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-62 · Cited by 27
Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis
Zhou, S., Kishi, N., Alerasool, P., & Rohs, N. C. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01073-w · Cited by 30
Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: A systematic review of completed and ongoing studies
Choy, H., Gerber, D. E., Bradley, J. D., Iyengar, P., Monberg, M., Treat, J., Govindan, R., Koustensis, A., Barker, S. S., & Obasaju, C. K. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2014.12.003 · Cited by 26
Interstitial lung disease induced by gefitinib and Toll-like receptor ligands is mediated by Fra-1
Takada, Y., Gresh, L., Bözec, A., Ikeda, E., Kamiya, K., Watanabe, M., Kobayashi, K., Asano, K., Toyama, Y., Wagner, E. F., et al. (2011) · Oncogene · doi:10.1038/onc.2011.101 · Cited by 26
Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients
Beom, S., Kim, D., Sim, S. H., Keam, B., Park, J. H., Lee, J., Kim, T. M., Lee, S., & Heo, D. S. (2015) · Cancer Research and Treatment · doi:10.4143/crt.2014.201 · Cited by 26
Self-citation
Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer
Berardi, R., Santoni, M., Morgese, F., Ballatore, Savini, Onofri, Mazzanti, Pistelli, M., Pierantoni, R., Lisa, D., et al. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s28155 · Cited by 25
EGFR tyrosine kinase inhibitorsversuschemotherapy inEGFRwild-type pre-treated advanced nonsmall cell lung cancer in daily practice
Tomasini, P., Brosseau, S., Mazières, J., Merlio, J., Beau‐Faller, M., Mosser, J., Wislez, M., Ouafik, L., Besse, B., Rouquette, I., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00514-2017 · Cited by 27
Health-Related Quality of Life in Advanced Non-small Cell Lung Cancer: A Methodological Appraisal Based on a Systematic Literature Review
van der Weijst, L., Lievens, Y. N., Schrauwen, W., & Surmont, V. F. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00715 · Cited by 25
Safety of gefitinib in non-small cell lung cancer treatment
Hsiue, E. H.-C., Lee, J., Lin, C., & Yang, J. C. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1192605 · Cited by 25
Self-citation
Gefitinib for the treatment of non-small-cell lung cancer
Campbell, L., Blackhall, F. H., & Thatcher, N. J. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.481283 · Cited by 25
Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: A real-world cost-effectiveness analysis
Cromwell, I., van der Hoek, K., Taylor, S. C. M., Melosky, B. L., & Peacock, S. J. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2011.12.003 · Cited by 24
Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials.
Osarogiagbon, R. U., Cappuzzo, F., Ciuleanu, T., Leon, L., & Klughammer, B. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2015.07.17 · Cited by 23
Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents
Escalante, C. P., Chang, Y.-C., Liao, K.-P. E., Rouleau, T., Halm, J. K., Bossi, P., Bhadriraju, S., Brito-Dellan, N., Sahai, S. K., Yusuf, S. W., et al. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3310-3 · Cited by 24
The Efficacy and Toxicity of Gefitinib in Treating Non-small Cell Lung Cancer: A Meta-analysis of 19 Randomized Clinical Trials
Wo, H., He, J., Zhao, Y., Yu, H., Chen, F., & Yi, H. (2018) · Journal of Cancer · doi:10.7150/jca.23356 · Cited by 22
Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non–Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized Trials
Vale, C. L., Burdett, S., Fisher, D. J., Navani, N., Parmar, M., Copas, A. J., & Tierney, J. F. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.11.007 · Cited by 22
Risk of Fatal Pulmonary Events in Patients with Advanced Non-Small-Cell Lung Cancer Treated with EGF Receptor Tyrosine Kinase Inhibitors: A Comparative Meta-Analysis
Abdel-Rahman, O. M., & Elhalawani, H. M. (2015) · Future Oncology · doi:10.2217/fon.15.16 · Cited by 20
Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer
Kotsakis, A. P., & Georgoulias, V. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.498581 · Cited by 20
Efficacy of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Patients with/without EGFR-Mutation: Evidence Based on Recent Phase III Randomized Trials
Li, H. (2014) · Medical Science Monitor · doi:10.12659/msm.892476 · Cited by 19
The Efficacy of Bevacizumab Compared with Other Targeted Drugs for Patients with Advanced NSCLC: A Meta-Analysis from 30 Randomized Controlled Clinical Trials
Cui, J., Cai, X., Zhu, M., Liu, T., & Zhao, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062038 · Cited by 17
Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer
Yuan, Y., Li, X., Chen, J., Dong, Weng, S., & Huang, J. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s34124 · Cited by 17
Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis
Sohn, H. S., Kwon, J., Shin, S., Kim, H., & Kim, H. (2015) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12332 · Cited by 17
Self-citation
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients With EGFR Wild-Type Non–Small-Cell Lung Cancer: The Never-Ending Story
Gelsomino, F., Agustoni, F., Niger, M., Valota, M., & Haspinger, E. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.2617 · Cited by 17
Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials
Jiang, J., Huang, L., Liang, X., Zhou, X., Huang, R., Chu, Z., & Zhan, Q. (2010) · Acta Oncologica · doi:10.3109/0284186x.2010.546368 · Cited by 16

Authors: Lee, D. H., Park, K., Kim, J. H., Lee, J.-S., Shin, S. W., Kang, J.-H., Ahn, M.-J., Ahn, J. S., Suh, C., & Kim, S.-W.
Affiliations: Authors' Affiliations: 1Asan Medical Center, University of Ulsan College of Medicine; 2Samsung Medical Center, Sungkyunkwan University; 3Yonsei University Medical Center; 4Korea University Anam Hospital; 5Catholic University Kangnam St. Mary's Hospital, Seoul, Korea; and 6Seoul National University Bundang Hospital, Sungnam, Korea
Yonsei University (KR)
Corresponding author: Kim, Sang-We
ORCID: Park, Keunchil
Lee, Jong-Seok
Shin, Sang Won
Kang, Jin-Hyoung
Ahn, Myung-Ju
Ahn, Jin Seok
Suh, Cheolwon
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2010-02-15
Volume: 16
Issue: 4
Pages: 1307-1314
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-09-1903
OpenAlex: W2118548009
Cited by: 179
References: 16
Citations by year: 2026: 1 · 2025: 2 · 2024: 4 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 4 · 2019: 3 · 2018: 7 · 2017: 9 · 2016: 14 · 2015: 20 · 2014: 19 · 2013: 27 · 2012: 24
FWCI: 23.47
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: gefitinib, docetaxel, non-small cell lung cancer, second-line therapy, platinum-based chemotherapy, progression-free survival, objective response rate, interstitial lung disease, adverse events, quality of life, EGFR tyrosine kinase inhibitors
MeSH terms: Docetaxel, Gefitinib, Adult, Aged, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Quinazolines, Time Factors, Platinum Compounds, Disease-Free Survival, Retreatment, Taxoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks